Patents by Inventor Hank Mansbach

Hank Mansbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS OF TREATMENT FOR SEVERE HYPERTRIGLYCERIDEMIA
    Publication number: 20250170249
    Abstract: Compositions, methods and therapeutic regimens of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.
    Type: Application
    Filed: June 4, 2024
    Publication date: May 29, 2025
    Applicant: 89bio, Inc.
    Inventors: Hank Mansbach, Leo Tseng
  • Methods of treatment using mutant FGF-21 peptide conjugates
    Patent number: 12037376
    Abstract: Therapeutic regimens and uses of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates comprising a polyethylene glycol (PEG) moiety attached to a mutant FGF-21 peptide via a glycosyl moiety thereof in the treatment of nonalcoholic steatohepatitis are provided.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: July 16, 2024
    Assignee: 89bio Ltd.
    Inventors: Hank Mansbach, Chih-Ming Tseng
  • Compositions and methods of treatment for severe hypertriglyceridemia
    Patent number: 12036284
    Abstract: Compositions, methods and therapeutic regimens of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.
    Type: Grant
    Filed: June 23, 2023
    Date of Patent: July 16, 2024
    Assignee: 89bio, Inc.
    Inventors: Hank Mansbach, Leo Tseng
  • COMPOSITIONS AND METHODS OF TREATMENT FOR SEVERE HYPERTRIGLYCERIDEMIA
    Publication number: 20230414768
    Abstract: Compositions, methods and therapeutic regimens of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates for the treatment of severe hypertriglyceridemia are provided.
    Type: Application
    Filed: June 23, 2023
    Publication date: December 28, 2023
    Applicant: 89bio, Inc.
    Inventors: Hank Mansbach, Leo Tseng
  • METHODS OF TREATMENT USING MUTANT FGF-21 PEPTIDE CONJUGATES
    Publication number: 20220306712
    Abstract: Therapeutic regimens and uses of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates comprising a polyethylene glycol (PEG) moiety attached to a mutant FGF-21 peptide via a glycosyl moiety thereof in the treatment of nonalcoholic steatohepatitis are provided.
    Type: Application
    Filed: June 16, 2022
    Publication date: September 29, 2022
    Inventors: Hank MANSBACH, Chih-Ming TSENG
  • Methods of treatment using mutant FGF-21 peptide conjugates
    Patent number: 11427623
    Abstract: Therapeutic regimens and uses of mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugates comprising a polyethylene glycol (PEG) moiety attached to a mutant FGF-21 peptide via a glycosyl moiety thereof in the treatment of nonalcoholic steatohepatitis are provided.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: August 30, 2022
    Assignee: 89BIO LTD.
    Inventors: Hank Mansbach, Chih-Ming Tseng